



- (51) **International Patent Classification:**
A61K 31/4409 (2006.01)
- (21) **International Application Number:**
PCT/US2012/047513
- (22) **International Filing Date:**
20 July 2012 (20.07.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/510,559 22 July 2011 (22.07.2011) US
- (71) **Applicant (for all designated States except US):** **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Group Limited, Glaxo Wellcome House, Berkeley Avenue, Greenford (GB).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **BIS, Joanna** [US/US]; 130 Trafalgar Lane, Cary, NC 27513 (US). **IGO, David, H.** [US/US]; Five Moore Drive, Research Triangle Park, NC 27709 (US).
- (74) **Agents:** **LUTOMSKI, Kathryn, A.** et al.; Glaxosmithkline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King Of Prussia, PA 19406-0939 (US).

- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** POLYMORPHIC FORMS OF THE SODIUM SALT OF 4-TERT-BUTYL -N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENE SULFONAMIDE




FIG. 1

(57) **Abstract:** Disclosed are novel polymorphic solvated and desolvated forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)phenyl]-benzenesulfonamide. One embodiment of the present invention is directed to a crystalline sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]benzenesulfonamide (hereinafter "Compound A-1,4-dioxane/water solvate"), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles ($^{\circ}2\theta$), when measured using Cu K α radiation, at about 4.0, 8.1, 10.1, 14.2, 16.2, 18.6, 20.3, 24.7, 25.0, and 26.5.

WO 2013/016156 A1

POLYMORPHIC FORMS OF THE SODIUM SALT OF 4-TERT-BUTYL-N-[4-
CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-
BENZENESULFONAMIDE

5 BACKGROUND OF THE INVENTION


In the pursuit of a developable form of a solid, orally-administered pharmaceutical compound, a number of specific features are sought. Although an amorphous form of a pharmaceutical compound may be developed, compounds having high crystallinity are generally preferred. Often such highly crystalline compounds are salts.

International Publication Number WO 2004/046092 describes a series of compounds which are indicated as antagonists of the CCR9 receptor, and which are indicated as being useful in the treatment of CCR9-mediated disorders. Specifically disclosed in that application is the compound 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide. Identification of a stable, crystalline form of such compound with suitable properties for oral administration would be highly desirable for the treatment of CCR9-mediated diseases.

SUMMARY OF THE INVENTION

20

The present invention relates to novel polymorphic solvated or desolvated forms of the sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide (hereinafter "Compound A"). The compounds of the invention are represented by Structure (I):



25

Specifically, compounds where X is a solvent or solvent mixture such as 1,4-dioxane/water, formamide, dimethylsulfoxide, or water, or where X is absent. The compounds of this invention are useful for antagonizing the CCR9 receptor, and for

treating diseases such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

BRIEF DESCRIPTION OF THE DRAWINGS

5

Fig. 1 shows an X-ray powder diffraction pattern of Compound A - 1,4-dioxane/water solvate.

Fig. 2 shows an X-ray powder diffraction pattern of Compound A - formamide solvate.

Fig. 3 shows an X-ray powder diffraction pattern of Compound A - dimethylsulfoxide
10 solvate.

Fig. 4 shows an X-ray powder diffraction pattern of Compound A - desolvated crystalline form.

Fig. 5 shows an X-ray powder diffraction pattern of Compound A - hydrate.

Fig. 6 shows a Raman spectrum of Compound A - 1,4-dioxane/water solvate.

15

Fig. 7 shows a Raman spectrum of Compound A - formamide solvate.

Fig. 8 shows a Raman spectrum of Compound A - dimethylsulfoxide solvate.

Fig. 9 shows a Raman spectrum of Compound A - desolvated crystalline form.

Fig. 10 shows a differential scanning calorimetry trace of Compound A -
1,4-dioxane/water solvate.

20

Fig. 11 shows a differential scanning calorimetry trace of Compound A - formamide solvate.

Fig. 12 shows a differential scanning calorimetry trace of Compound A -
dimethylsulfoxide solvate.

25

Fig. 13 shows a differential scanning calorimetry trace of Compound A - desolvated
crystalline form.

Fig. 14 shows a thermogravimetric analysis trace of Compound A - 1,4-dioxane/water solvate.

Fig. 15 shows a thermogravimetric analysis trace of Compound A - formamide solvate.

Fig. 16 shows a thermogravimetric analysis trace of Compound A - dimethylsulfoxide solvate.

Fig. 17 shows a thermogravimetric analysis trace of Compound A - desolvated crystalline form.

5 Fig. 18 shows a thermogravimetric analysis trace of Compound A - hydrate.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to novel polymorphic solvated and desolvated
10 forms of the sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide. One embodiment of the present invention is directed to a crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide (hereinafter “Compound A - 1,4-dioxane/water solvate”), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising
15 diffraction angles ($^{\circ}2\theta$), when measured using Cu K_{α} radiation, at about 4.0, 8.1, 10.1, 14.2, 16.2, 18.6, 20.3, 24.7, 25.0, and 26.5.

Another embodiment of the present invention is directed to Compound A - 1,4-dioxane/water solvate, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with Fig. 1.

20 Another embodiment of the present invention is directed to Compound A - 1,4-dioxane/water solvate, wherein the crystalline form provides a Raman spectrum containing peaks at about 668, 743, 804, 1125, 1154, 1162, 1286, 1544, 1587, 1597, 1611, 1657, and 1672 cm^{-1} .

25 Another embodiment of the present invention is directed to Compound Compound A - 1,4-dioxane/water solvate, wherein the crystalline form provides a Raman spectrum substantially in accordance with Fig. 6.

30 Another embodiment of the present invention is directed to Compound A - 1,4-dioxane/water solvate, wherein the crystalline form provides a differential scanning calorimetry trace substantially in accordance with Fig. 10 and/or a thermogravimetric analysis trace substantially in accordance with Fig. 14.

Another embodiment of the present invention is directed to a crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-

benzenesulfonamide (hereinafter “Compound A - formamide solvate”), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles ($^{\circ}2\theta$), when measured using Cu K_{α} radiation, at about 5.9, 8.6, 12.1, 12.7, 16.1, 16.9, 17.4, 17.8, 18.0, 20.4, 20.6, 21.7, 22.6, 23.7, 23.9, 24.3, 25.9, 26.3, 26.5,
5 26.9, 27.9, 30.9, and 38.6.

Another embodiment of the present invention is directed to Compound A - formamide solvate, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with Fig. 2.

Another embodiment of the present invention is directed to Compound A -
10 formamide solvate, wherein the crystalline form provides a Raman spectrum containing peaks at about 655, 668, 737, 804, 1079, 1099, 1123, 1161, 1229, 1303, 1465, 1537, 1595, 1611, and 1654 cm^{-1} .

Another embodiment of the present invention is directed to Compound Compound A - formamide solvate, wherein the crystalline form provides a Raman spectrum
15 substantially in accordance with Fig. 7.

Another embodiment of the present invention is directed to Compound A - formamide solvate, wherein the crystalline form provides a differential scanning calorimetry trace substantially in accordance with Fig. 11 and/or a thermogravimetric analysis trace substantially in accordance with Fig. 15.

Another embodiment of the present invention is directed to a crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide (hereinafter “Compound A - dimethylsulfoxide solvate”), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles ($^{\circ}2\theta$), when measured using Cu K_{α} radiation, at about 5.6, 8.0, 10.8,
20 15.7, 17.0, 17.7, 18.0, 18.1, 18.4, 21.2, 21.8, 22.5, 22.8, 24.3, 28.6, 29.7, and 34.5.

Another embodiment of the present invention is directed to Compound A - dimethylsulfoxide solvate, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with Fig. 3.

Another embodiment of the present invention is directed to Compound A -
30 dimethylsulfoxide solvate, wherein the crystalline form provides a Raman spectrum containing peaks at about 662, 672, 718, 729, 750, 799, 1078, 1109, 1158, 1236, 1302, 1536, 1588, 1596, and 1636 cm^{-1} .

Another embodiment of the present invention is directed to Compound Compound A - dimethylsulfoxide solvate, wherein the crystalline form provides a Raman spectrum substantially in accordance with Fig. 8.

Another embodiment of the present invention is directed to Compound A -
5 dimethylsulfoxide solvate, wherein the crystalline form provides a differential scanning calorimetry trace substantially in accordance with Fig. 12 and/or a thermogravimetric analysis trace substantially in accordance with Fig. 16.

Another embodiment of the present invention is directed to a crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-
10 benzenesulfonamide (hereinafter "Compound A - desolvated crystalline form"), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles ($^{\circ}2\theta$), when measured using Cu K_{α} radiation, at about 6.5, 9.6, 10.6, 11.9, 14.4, 16.1, 17.7, 17.9, 19.3, 21.1, 22.0, 22.2, 23.4, 23.6, 24.4, 26.3, 27.7, 28.5, and 29.5.

Another embodiment of the present invention is directed to Compound A -
15 desolvated crystalline form, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with Fig. 4.

Another embodiment of the present invention is directed to Compound A -
desolvated crystalline form, wherein the crystalline form provides a Raman spectrum
20 containing peaks at about 654, 667, 737, 803, 855, 1077, 1122, 1160, 1311, 1461, 1536, 1592, 1609, and 1648 cm^{-1} .

Another embodiment of the present invention is directed to Compound Compound A - desolvated crystalline form, wherein the crystalline form provides a Raman spectrum substantially in accordance with Fig. 9.

Another embodiment of the present invention is directed to Compound A -
25 desolvated crystalline form, wherein the crystalline form provides a differential scanning calorimetry trace substantially in accordance with Fig. 13 and/or a thermogravimetric analysis trace substantially in accordance with Fig. 17.

Another embodiment of the present invention is directed to a crystalline sodium
30 salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide (hereinafter "Compound A - hydrate"), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles

($^{\circ}2\theta$), when measured using Cu K_{α} radiation, at about 6.1, 12.4, 15.9, 16.4, 16.9, 17.8, 18.0, 19.1, 23.4, and 25.0.

Another embodiment of the present invention is directed to Compound A - hydrate, wherein the crystalline form is characterized by an X-ray powder diffraction pattern
5 substantially in accordance with Fig. 5.

Another embodiment of the present invention is directed to Compound A - hydrate, wherein the crystalline form provides a thermogravimetric analysis trace substantially in accordance with Fig. 18.

It is well known and understood to those skilled in the art that the apparatus
10 employed, humidity, temperature, orientation of the powder crystals, and other parameters involved in obtaining an X-ray powder diffraction (XRPD) pattern may cause some variability in the appearance, intensities, and positions of the lines in the diffraction pattern. An X-ray powder diffraction pattern that is “substantially in accordance” with that of Figures 1, 2, 3, 4, or 5 provided herein is an XRPD pattern that would be considered by
15 one skilled in the art to represent a compound possessing the same crystal form as the compound that provided the XRPD pattern of Figures 1, 2, 3, 4, or 5. That is, the XRPD pattern may be identical to that of Figures 1, 2, 3, 4, or 5, or more likely it may be somewhat different. Such an XRPD pattern may not necessarily show each of the lines of the diffraction patterns presented herein, and/or may show a slight change in appearance,
20 intensity, or a shift in position of said lines resulting from differences in the conditions involved in obtaining the data. A person skilled in the art is capable of determining if a sample of a crystalline compound has the same form as, or a different form from, a form disclosed herein by comparison of their XRPD patterns. For example, one skilled in the art can overlay an XRPD pattern of a sample of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-
25 2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, with Fig. 1 and, using expertise and knowledge in the art, readily determine whether the XRPD pattern of the sample is substantially in accordance with the XRPD pattern of Compound A -
1,4-dioxane/water solvate. If the XRPD pattern is substantially in accordance with Fig. 1, the sample form can be readily and accurately identified as having the same form as
30 Compound A - 1,4-dioxane/water solvate. Similarly, a person skilled in the art is capable of determining if a given diffraction angle (expressed in $^{\circ}2\theta$) obtained from an XRPD pattern is at about the same position as a value presented herein.

“A compound of the invention” means a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, specifically the crystalline forms defined herein as Compound A - 1,4-dioxane/water solvate, Compound A - formamide solvate, Compound A - dimethylsulfoxide solvate, Compound A - desolvated
5 crystalline form, and Compound A - hydrate.

The invention includes a therapeutic method for treating or ameliorating a CCR9-mediated disorder in a subject in need thereof comprising administering to a subject in need thereof an effective amount of a compound of the invention or a composition comprising an effective amount of a compound of the invention and an optional
10 pharmaceutically acceptable carrier.

As used herein, the phrase "CCR9-mediated disorder" and related phrases and terms refer to a condition or disease characterized by inappropriate, i.e., less than or greater than normal, CCR9 functional activity. Inappropriate CCR9 functional activity might arise as the result of CCR9 expression in cells which normally do not express
15 CCR9, increased CCR9 expression (leading to, e.g., inflammatory and immunoregulatory disorders and diseases) or decreased CCR9 expression. Inappropriate CCR9 functional activity might also arise as the result of TECK secretion by cells which normally do not secrete TECK, increased TECK expression (leading to, e.g., inflammatory and immunoregulatory disorders and diseases) or decreased TECK expression. A CCR9-
20 mediated disorder may be completely or partially mediated by inappropriate CCR9 functional activity. However, a CCR9-mediated disorder is one in which modulation of CCR9 results in some effect on the underlying condition or disease (e.g., a CCR9 antagonist results in some improvement in patient well being in at least some patients).

“Effective amount” means that amount of drug substance (i.e. a compound of the present invention) that elicits the desired biological response in a subject. Such response
25 includes alleviation of the symptoms of the disease or disorder being treated. The effective amount of a compound of the invention in such a therapeutic method is about 0.001 to 100 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 mg/kg per day. A suitable dosage level may be about
30 0.01 to 25 mg/kg per day, about 0.05 to 10 mg/kg per day, or about 0.1 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5, 0.5 to 5.0, or 5.0 to 50 mg/kg per day. For oral administration, the compositions are preferably provided in the

form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

It is to be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including age, body weight, hereditary characteristics, general health, gender, diet, mode and time of administration, rate of excretion, drug combination, and the nature and severity of the particular condition being treated.

Administration methods include administering an effective amount of a compound or composition of the invention at different times during the course of therapy or concurrently in a combination form. The methods of the invention include all known therapeutic treatment regimens.

Diseases and conditions associated with inflammation, immune disorders, infection and cancer may be treated or prevented with the present compounds, compositions, and methods. In one group of embodiments, diseases or conditions, including chronic diseases, of humans or other species can be treated with an inhibitor of CCR9 function. These diseases or conditions include: (1) allergic diseases such as systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies and food allergies, (2) inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, ileitis and enteritis, (3) vaginitis, (4) psoriasis and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria and pruritus, (5) vasculitis, (6) spondyloarthropathies, (7) scleroderma, (8) asthma and respiratory allergic diseases such as allergic asthma, allergic rhinitis, hypersensitivity lung diseases and the like, (9) autoimmune diseases, such as fibromyalgia, scleroderma, ankylosing spondylitis, juvenile RA, Still's disease, polyarticular juvenile RA, pauciarticular juvenile RA, polymyalgia rheumatica, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, polyarticular arthritis, multiple sclerosis, systemic lupus erythematosus, type I diabetes, type II diabetes, glomerulonephritis, and the like, (10) graft rejection (including allograft rejection), (11) graft-v-host disease (including both acute and chronic), (12) other diseases in which undesired inflammatory responses are to be inhibited, such as atherosclerosis, myositis, neurodegenerative diseases (e.g., Alzheimer's disease), encephalitis, meningitis, hepatitis,

nephritis, sepsis, sarcoidosis, allergic conjunctivitis, otitis, chronic obstructive pulmonary disease, sinusitis, Behcet's syndrome and gout, (13) pulmonary fibrosis and other fibrotic diseases, and (14) irritable bowel syndrome.

Preferably, the present methods are directed to the treatment of diseases or
5 conditions selected from inflammatory bowel disease, including Crohn's disease and ulcerative colitis; allergic diseases such as psoriasis, atopic dermatitis, and asthma; and autoimmune diseases such as rheumatoid arthritis.

More preferably, the present methods are directed to the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

10 The compounds and compositions of the present invention can be combined with other compounds and compositions having related utilities to prevent and treat the condition or disease of interest, such as inflammatory conditions and diseases, including inflammatory bowel disease, allergic diseases, psoriasis, atopic dermatitis and asthma, and those pathologies noted above. Selection of the appropriate agents for use in combination
15 therapies can be made one of ordinary skill in the art. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

The weight ratio of a compound of the present invention to the second active
20 ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with an NSAID the weight ratio of a compound of the present invention to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present
25 invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.

Combination therapy includes co-administration of a compound of the invention and said other agent, sequential administration of a compound of the invention and the other agent, administration of a composition containing a compound of the invention and
30 the other agent, or simultaneous administration of separate compositions containing a compound of the invention and the other agent.

The invention further includes the use of a compound of the invention as an active therapeutic substance, in particular in the treatment of CCR9-mediated disorders. In

particular, the invention includes the use of a compound of the invention in the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

In another aspect, the invention includes the use of compounds of the invention in the manufacture of a medicament for use in the treatment of the above disorders.

5 “Pharmaceutically acceptable carrier” means any one or more compounds and/or compositions that are of sufficient purity and quality for use in the formulation of a compound of the invention that, when appropriately administered to a human, do not produce an adverse reaction, and that are used as a vehicle for a drug substance (i.e. a compound of the present invention).

10 The invention further includes the process for making the composition comprising mixing a compound of the invention and an optional pharmaceutically acceptable carrier; and includes those compositions resulting from such a process, which process includes conventional pharmaceutical techniques. For example, a compound of the invention may be nanomilled prior to formulation. A compound of the invention may also be prepared by
15 grinding, micronizing or other particle size reduction methods known in the art. Such methods include, but are not limited to, those described in U.S. Pat. Nos. 4,826,689, 5,145,684, 5,298,262, 5,302,401, 5,336,507, 5,340,564, 5,346,702, 5,352,459, 5,354,560, 5,384,124, 5,429,824, 5,503,723, 5,510,118, 5,518,187, 5,518,738, 5,534,270, 5,536,508, 5,552,160, 5,560,931, 5,560,932, 5,565,188, 5,569,448, 5,571,536, 5,573,783, 5,580,579,
20 5,585,108, 5,587,143, 5,591,456, 5,622,938, 5,662,883, 5,665,331, 5,718,919, 5,747,001, PCT applications WO 93/25190, WO 96/24336, and WO 98/35666, each of which is incorporated herein by reference. The pharmaceutical compositions of the invention may be prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences
25 (Mack Publishing Company), the entire teachings of which are incorporated herein by reference.

The compositions of the invention include ocular, oral, nasal, transdermal, topical with or without occlusion, intravenous (both bolus and infusion), and injection (intraperitoneally, subcutaneously, intramuscularly, intratumorally, or parenterally). The
30 composition may be in a dosage unit such as a tablet, pill, capsule, powder, granule, liposome, ion exchange resin, sterile ocular solution, or ocular delivery device (such as a contact lens and the like facilitating immediate release, timed release, or sustained release), parenteral solution or suspension, metered aerosol or liquid spray, drop, ampoule, auto-

injector device, or suppository; for administration ocularly, orally, intranasally, sublingually, parenterally, or rectally, or by inhalation or insufflation.

Compositions of the invention suitable for oral administration include solid forms such as pills, tablets, caplets, capsules (each including immediate release, timed release, and sustained release formulations), granules and powders.

The oral composition is preferably formulated as a homogeneous composition, wherein the drug substance (i.e. a compound of the present invention) is dispersed evenly throughout the mixture, which may be readily subdivided into dosage units containing equal amounts of a compound of the invention. Preferably, the compositions are prepared by mixing a compound of the invention with one or more optionally present pharmaceutical carriers (such as a starch, sugar, diluent, granulating agent, lubricant, glidant, binding agent, and disintegrating agent), one or more optionally present inert pharmaceutical excipients (such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and syrup), one or more optionally present conventional tableting ingredients (such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, and any of a variety of gums), and an optional diluent (such as water).

Binding agents include starch, gelatin, natural sugars (e.g. glucose and beta-lactose), corn sweeteners and natural and synthetic gums (e.g. acacia and tragacanth). Disintegrating agents include starch, methyl cellulose, agar, and bentonite.

A compound of the invention may also be administered *via* a delayed release composition, wherein the composition includes a compound of the invention and a biodegradable slow release carrier (e.g. a polymeric carrier) or a pharmaceutically acceptable non-biodegradable slow release carrier (e.g. an ion exchange carrier).

Biodegradable and non-biodegradable delayed release carriers are well known in the art. Biodegradable carriers are used to form particles or matrices which retain a drug substance(s) (i.e. a compound of the present invention) and which slowly degrade/dissolve in a suitable environment (e.g. aqueous, acidic, basic and the like) to release the drug substance(s). Such particles degrade/dissolve in body fluids to release the drug substance(s) (i.e. compounds of the present invention) therein. The particles are preferably nanoparticles (e.g. in the range of about 1 to 500 nm in diameter, preferably about 50-200 nm in diameter, and most preferably about 100 nm in diameter). In a process for preparing a slow release composition, a slow release carrier and a compound of the invention are

first dissolved or dispersed in an organic solvent. The resulting mixture is added into an aqueous solution containing an optional surface-active agent(s) to produce an emulsion. The organic solvent is then evaporated from the emulsion to provide a colloidal suspension of particles containing the slow release carrier and a compound of the invention.

5 Tablets and capsules represent an advantageous oral dosage unit form. Tablets may be sugarcoated or filmcoated using standard techniques. Tablets may also be coated or otherwise compounded to provide a prolonged, control-release therapeutic effect. The dosage form may comprise an inner dosage and an outer dosage component, wherein the outer component is in the form of an envelope over the inner component. The two
10 components may further be separated by a layer which resists disintegration in the stomach (such as an enteric layer) and permits the inner component to pass intact into the duodenum or a layer which delays or sustains release. A variety of enteric and non-enteric layer or coating materials (such as polymeric acids, shellacs, acetyl alcohol, and cellulose acetate or combinations thereof) may be used.

15 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.

EXAMPLE 1

Preparation of:

An anhydrous crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

25 A reaction vessel was charged with 300 g 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, 4,737 mL Industrial Methylated Spirits (IMS), and 302.4 mL water. 27.245 g sodium hydroxide pellets were added to the slurry at 25 °C. The reaction mixture was agitated at ambient temperature for 50 minutes, followed
30 by heating to ~78 °C to dissolve all solids. The clear solution was then filtered while maintaining the temperature above 55 °C throughout the filtration process. After filtration, the filtered solution was reheated to 75 °C and then cooled to 55 °C and seeded with 3.0 g Compound B - anhydrous crystalline form (prepared by an analogous procedure) as a slurry in 15 mL IMS at ambient temperature. The slurry was held at 55 °C overnight and

then cooled to 45 °C. Vacuum distillation was employed while heating the reactor jacket to 65 °C and not allowing the slurry temperature to exceed 55 °C, leaving ~1,500 mL of slurry in the reactor. The slurry was cooled to -10 °C, held at that temperature overnight, and then transferred to a filter dryer and settled for 10 minutes. The jacket temperature of the filter was pre-chilled to -10 °C. The mother liquors were removed to break-through using 0.5 to 1 bar nitrogen pressure. The crystallizer was charged with a first pre-chilled wash of 1,200 mL IMS, chilled to -10 °C. The wash was transferred to the cake in the filter, agitated for 10 minutes, settled for 10 minutes, and removed under 0.5 to 1 bar nitrogen pressure. The washing of the filter cake was repeated two additional times under the same conditions. The jacket temperature of the filter was increased to 20 °C and the cake was blown-down under 0.5 to 1 bar nitrogen pressure until the solvent being removed was reduced to a trickle. The wet cake was dried at 70 °C with agitation under vacuum to provide 258.3 g of the title compound as a yellow crystalline solid.

15

EXAMPLE 2

Preparation of:

A crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide (Compound A - 1,4-dioxane/water solvate)

20

100 mg of an anhydrous crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide was weighed into a 1.8-mL vial containing a stir bar. Water (43.9 µL), 1,4-dioxane (53.0 µL), and 1 M sodium hydroxide (4.3 µL) were added, the vial was tightly capped, and the solution was stirred for 5 days at 25 °C. The resulting solid was isolated using a Büchner funnel, and the filter cake was air-dried for 1 hour to provide the title compound as a yellow solid.

25

The X-ray powder diffraction (XRPD) pattern of this material is shown in Fig. 1 and a summary of the diffraction angles and d-spacings is given in Table I. The XRPD analysis was conducted on a PANalytical X'Pert Pro Diffractometer, model PW3040/60, serial number DY2407 using an X'Celerator detector. The acquisition conditions included: Cu K_α radiation ($\lambda = 1.54059 \text{ \AA}$), generator tension: 45kV, generator current: 40mA, start angle: 2.0°2 θ , end angle: 50.0°2 θ , step size: 0.0167°2 θ , time per step: 40.005 seconds. The sample was prepared using zero background (front fill) technique.

30

TABLE I

Diff. Angle [$^{\circ}2\theta$]	d-spacing [\AA]
4.0111	22.01079
8.0656	10.95305
10.0893	8.76019
14.1627	6.24847
16.197	5.46795
18.6342	4.75791
20.3118	4.36857
24.6832	3.60392
24.9557	3.56518
26.5095	3.35963

The Raman spectrum of the title compound was recorded on a Nicolet NXR 9650 FT-Raman Spectrometer, at 4 cm^{-1} resolution with excitation from a Nd:YVO₄ laser ($\lambda =$
5 1064 nm). The Raman spectrum of this material is shown in Fig. 6 with major peaks observed at 668, 743, 804, 1125, 1154, 1162, 1286, 1544, 1587, 1597, 1611, 1657, and 1672 cm^{-1} .

The differential scanning calorimetry (DSC) thermogram of the title compound was recorded on a TA Instruments Q1000 Differential Scanning Calorimeter and is shown
10 in Fig. 10. The sample was weighed into an aluminium pan, a pan lid placed on top and lightly crimped without sealing the pan. The experiments were conducted using a heating rate of $15\text{ }^{\circ}\text{C}/\text{min}$.

The thermogravimetric analysis (TGA) thermogram of the title compound was recorded on a TA Instruments Q5000 Thermogravimetric Analyzer and is shown in Fig.
15 14. The experiments were conducted using a heating rate of $15\text{ }^{\circ}\text{C}/\text{min}$.

EXAMPLE 3

Preparation of:

A crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-
20 phenyl]-benzenesulfonamide (Compound A - formamide solvate)

300 mg of an anhydrous crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide was weighed into a 4-mL vial containing a stir bar. Dichloromethane ($1,050\text{ }\mu\text{L}$), formamide ($450\text{ }\mu\text{L}$), and 0.5 M

sodium methoxide (38.4 μL) were added sequentially. The suspension was heated to 40 $^{\circ}\text{C}$ and stirred for 30 minutes. The sample was cooled to 0 $^{\circ}\text{C}$ at 1 $^{\circ}\text{C}/\text{minute}$ and then stirred for an additional 30 minutes. The resulting solid was isolated using a Büchner funnel, and the filter cake was washed with cold dichloromethane (4 mL, pre-cooled to 1 $^{\circ}\text{C}$), and dried at 50 $^{\circ}\text{C}$ for 30 minutes to provide the title compound as a yellow solid.

The X-ray powder diffraction (XRPD) pattern of this material is shown in Fig. 2 and a summary of the diffraction angles and d-spacings is given in Table II. The XRPD analysis was conducted on a PANalytical X'Pert Pro Diffractometer, model PW3040/60, serial number DY2407 using an X'Celerator detector. The acquisition conditions included: Cu K_{α} radiation ($\lambda = 1.54059 \text{ \AA}$), generator tension: 45kV, generator current: 40mA, start angle: $2.0^{\circ}2\theta$, end angle: $50.0^{\circ}2\theta$, step size: $0.0167^{\circ}2\theta$, time per step: 40.005 seconds. The sample was prepared using zero background (front fill) technique.

TABLE II

Diff. Angle [$^{\circ}2\theta$]	d-spacing [\AA]
5.878	15.02355
8.6404	10.22566
12.0513	7.33805
12.6593	6.98695
16.125	5.4922
16.9097	5.23907
17.4114	5.08922
17.7555	4.99136
18.0075	4.92206
20.3906	4.35187
20.6226	4.30343
21.7359	4.08548
22.5655	3.93711
23.749	3.74352
23.8983	3.72046
24.2996	3.65992
25.8941	3.43805
26.2873	3.38752
26.5418	3.35561
26.8984	3.31193
27.9099	3.19415
30.8679	2.89447
38.6418	2.32818

The Raman spectrum of the title compound was recorded on a Nicolet NXR 9650 FT-Raman Spectrometer, at 4 cm^{-1} resolution with excitation from a Nd:YVO4 laser ($\lambda = 1064\text{ nm}$). The Raman spectrum of this material is shown in Fig. 7 with major peaks observed at 655, 668, 737, 804, 1079, 1099, 1123, 1161, 1229, 1303, 1465, 1537, 1595, 1611, and 1654 cm^{-1} .

The differential scanning calorimetry (DSC) thermogram of the title compound was recorded on a TA Instruments Q1000 Differential Scanning Calorimeter and is shown in Fig. 11. The sample was weighed into an aluminium pan, a pan lid placed on top and lightly crimped without sealing the pan. The experiments were conducted using a heating rate of $15\text{ }^{\circ}\text{C}/\text{min}$.

The thermogravimetric analysis (TGA) thermogram of the title compound was recorded on a TA Instruments Q5000 Thermogravimetric Analyzer and is shown in Fig. 15. The experiments were conducted using a heating rate of $15\text{ }^{\circ}\text{C}/\text{min}$.

15

EXAMPLE 4

Preparation of:

A crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide (Compound A - dimethylsulfoxide solvate)

20

100 mg of an anhydrous crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide was weighed into a 2-mL vial containing a stir bar. Chlorobenzene (350 μL), dimethylsulfoxide (150 μL), and 0.5 M sodium methoxide (12.5 μL) were added sequentially. The suspension was stirred at $25\text{ }^{\circ}\text{C}$ for 3 weeks. The resulting solid was isolated on filter paper, and the filter cake was dried at $40\text{ }^{\circ}\text{C}$ for 2 hours to provide the title compound.

25

The X-ray powder diffraction (XRPD) pattern of this material is shown in Fig. 3 and a summary of the diffraction angles and d-spacings is given in Table III. The XRPD analysis was conducted on a PANalytical X'Pert Pro Diffractometer, model PW3040/60, serial number DY2407 using an X'Celerator detector. The acquisition conditions included: Cu K_{α} radiation ($\lambda = 1.54059\text{ \AA}$), generator tension: 45kV, generator current: 40mA, start angle: $2.0^{\circ}2\theta$, end angle: $50.0^{\circ}2\theta$, step size: $0.0167^{\circ}2\theta$, time per step: 40.005 seconds. The sample was prepared using zero background (front fill) technique.

30

TABLE III

Diff. Angle [$^{\circ}2\theta$]	d-spacing [\AA]
5.5934	15.7874
7.9864	11.06143
10.7791	8.20108
15.6579	5.65498
16.9909	5.2142
17.7411	4.99539
17.9833	4.92863
18.1354	4.88764
18.4398	4.80765
21.2071	4.18612
21.7596	4.08107
22.5174	3.94542
22.7501	3.90558
24.2764	3.66338
28.5661	3.12225
29.694	3.00618
34.461	2.60046

The Raman spectrum of the title compound was recorded on a Nicolet NXR 9650 FT-Raman Spectrometer, at 4 cm^{-1} resolution with excitation from a Nd:YVO4 laser ($\lambda =$
5 1064 nm). The Raman spectrum of this material is shown in Fig. 8 with major peaks observed at 662, 672, 718, 729, 750, 799, 1078, 1109, 1158, 1236, 1302, 1536, 1588, 1596, and 1636 cm^{-1} .

The differential scanning calorimetry (DSC) thermogram of the title compound was recorded on a TA Instruments Q1000 Differential Scanning Calorimeter and is shown
10 in Fig. 12. The sample was weighed into an aluminium pan, a pan lid placed on top and lightly crimped without sealing the pan. The experiments were conducted using a heating rate of $15\text{ }^{\circ}\text{C}/\text{min}$.

The thermogravimetric analysis (TGA) thermogram of the title compound was recorded on a TA Instruments Q5000 Thermogravimetric Analyzer and is shown in Fig.
15 16. The experiments were conducted using a heating rate of $15\text{ }^{\circ}\text{C}/\text{min}$.

EXAMPLE 5

Preparation of:

A crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide (Compound A - desolvated crystalline form)

5

100 mg of a crystalline formamide solvate of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide (Compound A - formamide solvate) was placed onto an aluminum TGA pan and heated to 260 °C at a rate of 15 °C/minute using a TA Instruments Q5000 Thermogravimetric Analyzer to provide the title compound.

10

The X-ray powder diffraction (XRPD) pattern of this material is shown in Fig. 4 and a summary of the diffraction angles and d-spacings is given in Table IV. The XRPD analysis was conducted on a PANalytical X'Pert Pro Diffractometer, model PW3040/60, serial number DY2407 using an X'Celerator detector. The acquisition conditions included: Cu K_α radiation ($\lambda = 1.54059 \text{ \AA}$), generator tension: 45kV, generator current: 40mA, start angle: 2.0°2 θ , end angle: 50.0°2 θ , step size: 0.0167°2 θ , time per step: 40.005 seconds. The sample was prepared using zero background (front fill) technique.

15

TABLE IV

Diff. Angle [°2 θ]	d-spacing [Å]
6.4791	13.63095
9.586	9.21894
10.6185	8.32478
11.9048	7.42802
14.4414	6.12848
16.0781	5.50811
17.6985	5.0073
17.9351	4.94178
19.3172	4.59121
21.0851	4.21008
21.9857	4.03961
22.2374	3.99444
23.3765	3.80232
23.6316	3.76185
24.432	3.64039
26.2667	3.39013

27.7153	3.21614
28.5025	3.12908
29.5187	3.02363

The Raman spectrum of the title compound was recorded on a Nicolet NXR 9650 FT-Raman Spectrometer, at 4 cm⁻¹ resolution with excitation from a Nd:YVO4 laser ($\lambda = 1064$ nm). The Raman spectrum of this material is shown in Fig. 9 with major peaks
5 observed at 654, 667, 737, 803, 855, 1077, 1122, 1160, 1311, 1461, 1536, 1592, 1609, and 1648 cm⁻¹.

The differential scanning calorimetry (DSC) thermogram of the title compound was recorded on a TA Instruments Q1000 Differential Scanning Calorimeter and is shown in Fig. 13. The sample was weighed into an aluminium pan, a pan lid placed on top and
10 lightly crimped without sealing the pan. The experiments were conducted using a heating rate of 15 °C/min.

The thermogravimetric analysis (TGA) thermogram of the title compound was recorded on a TA Instruments Q5000 Thermogravimetric Analyzer and is shown in Fig. 17. The experiments were conducted using a heating rate of 15 °C/min.

15

EXAMPLE 6

Preparation of:

A crystalline sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide (Compound A - hydrate)

20

Approximately 30 mg of a desolvated crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide (Compound A - desolvated crystalline form) placed on a flat XRPD sample holder and left standing in a fume hood for 5 weeks to provide the title compound mixed with some of the
25 starting desolvated material.

The X-ray powder diffraction (XRPD) pattern of this material is shown in Fig. 5 and a summary of the diffraction angles and d-spacings is given in Table V. The XRPD analysis was conducted on a PANalytical X'Pert Pro Diffractometer, model PW3040/60, serial number DY2407 using an X'Celerator detector. The acquisition conditions
30 included: Cu K α radiation ($\lambda = 1.54059$ Å), generator tension: 45kV, generator current:

40mA, start angle: $2.0^{\circ}2\theta$, end angle: $50.0^{\circ}2\theta$, step size: $0.0167^{\circ}2\theta$, time per step: 40.005 seconds. The sample was prepared using zero background (front fill) technique.

TABLE V

Diff. Angle [$^{\circ}2\theta$]	d-spacing [\AA]
6.1432	14.37558
12.3809	7.14337
15.9257	5.56049
16.4099	5.39747
16.8501	5.25745
17.7646	4.98883
18.0388	4.9136
19.126	4.63667
23.443	3.79169
25.0165	3.55664

5

The thermogravimetric analysis (TGA) thermogram of the product was recorded on a TA Instruments Q5000 Thermogravimetric Analyzer and is shown in Fig. 18. The experiments were conducted using a heating rate of $15^{\circ}\text{C}/\text{min}$.

10

What is claimed is:

1. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern containing diffraction angles, when measured using Cu K α radiation, at about 4.0, 8.1, 10.1, 14.2, 16.2, 18.6, 20.3, 24.7, 25.0, and 26.5 °2 θ .
2. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with Figure 1.
3. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form provides a Raman spectrum containing peaks at about 668, 743, 804, 1125, 1154, 1162, 1286, 1544, 1587, 1597, 1611, 1657, and 1672 cm $^{-1}$.
4. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form provides a Raman spectrum substantially in accordance with Figure 6.
5. A pharmaceutical composition comprising the crystalline form according to any one of claims 1-4 and a pharmaceutically acceptable carrier.
6. A method of preparing a pharmaceutical composition comprising admixing the crystalline form according to any one of claims 1-4 and a pharmaceutically acceptable carrier.
7. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern containing diffraction angles, when measured using Cu K α radiation, at about 5.9, 8.6, 12.1, 12.7, 16.1, 16.9, 17.4, 17.8, 18.0, 20.4, 20.6, 21.7, 22.6, 23.7, 23.9, 24.3, 25.9, 26.3, 26.5, 26.9, 27.9, 30.9, and 38.6 °2 θ .

8. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with Figure 2.
9. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form provides a Raman spectrum containing peaks at about 655, 668, 737, 804, 1079, 1099, 1123, 1161, 1229, 1303, 1465, 1537, 1595, 1611, and 1654 cm⁻¹.
10. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form provides a Raman spectrum substantially in accordance with Figure 7.
11. A pharmaceutical composition comprising the crystalline form according to any one of claims 7-10 and a pharmaceutically acceptable carrier.
12. A method of preparing a pharmaceutical composition comprising admixing the crystalline form according to any one of claims 7-10 and a pharmaceutically acceptable carrier.
13. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern containing diffraction angles, when measured using Cu K_α radiation, at about 5.6, 8.0, 10.8, 15.7, 17.0, 17.7, 18.0, 18.1, 18.4, 21.2, 21.8, 22.5, 22.8, 24.3, 28.6, 29.7, and 34.5 °2θ.
14. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with Figure 3.
15. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form provides a Raman

spectrum containing peaks at about 662, 672, 718, 729, 750, 799, 1078, 1109, 1158, 1236, 1302, 1536, 1588, 1596, and 1636 cm^{-1} .

16. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form provides a Raman spectrum substantially in accordance with Figure 8.

17. A pharmaceutical composition comprising the crystalline form according to any one of claims 13-16 and a pharmaceutically acceptable carrier.

18. A method of preparing a pharmaceutical composition comprising admixing the crystalline form according to any one of claims 13-16 and a pharmaceutically acceptable carrier.

19. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern containing diffraction angles, when measured using $\text{Cu K}\alpha$ radiation, at about 6.5, 9.6, 10.6, 11.9, 14.4, 16.1, 17.7, 17.9, 19.3, 21.1, 22.0, 22.2, 23.4, 23.6, 24.4, 26.3, 27.7, 28.5, and 29.5 $^{\circ}2\theta$.

20. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with Figure 4.

21. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form provides a Raman spectrum containing peaks at about 654, 667, 737, 803, 855, 1077, 1122, 1160, 1311, 1461, 1536, 1592, 1609, and 1648 cm^{-1} .

22. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form provides a Raman spectrum substantially in accordance with Figure 9.

23. A pharmaceutical composition comprising the crystalline form according to any one of claims 19-22 and a pharmaceutically acceptable carrier.
24. A method of preparing a pharmaceutical composition comprising admixing the crystalline form according to any one of claims 19-22 and a pharmaceutically acceptable carrier.
25. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern containing diffraction angles, when measured using Cu K_α radiation, at about 6.1, 12.4, 15.9, 16.4, 16.9, 17.8, 18.0, 19.1, 23.4, and 25.0 °2θ.
26. A crystalline form of a sodium salt of 4-*tert*-butyl-*N*-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with Figure 5.
27. A pharmaceutical composition comprising the crystalline form according claim 25 or claim 26 and a pharmaceutically acceptable carrier.
28. A method of preparing a pharmaceutical composition comprising admixing the crystalline form according to claim 25 or claim 26 and a pharmaceutically acceptable carrier.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2012/047513

A. CLASSIFICATION OF SUBJECT MATTER IPC(8) - A61K 31/4409 (2012.01) USPC - 514/354 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC(8) - A61K 31/4409, 4425; C07D 213/50, 89 (2012.01) USPC - 514/354, 357, 358; 546/314, 328, 347, 348 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) PatBase, Orbit, STN, PubChem, Google Scholar		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2008/0161345 A1 (UNGASHE et al) 03 July 2008 (03.07.2008) entire document	1-28
A	US 2004/0038976 A1 (FLEMING et al) 26 February 2004 (26.02.2004) entire document	1-28
A	US 2005/0250820 A1 (CHEN) 10 November 2005 (10.11.2005) entire document	1-28
A	US 2010/0234364 A1 (BASAK et al) 16 September 2010 (16.09.2010) entire document	1-28
A	US 2011/0118248 A1 (UNGASHE et al) 19 May 2011 (19.05.2011) entire document	1-28
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/>		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 16 September 2012		Date of mailing of the international search report <div style="font-size: 2em; font-weight: bold; text-align: center;">28 SEP 2012</div>
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201		Authorized officer: Blaine R. Copenheaver PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774